Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.8%

61 terminated/withdrawn out of 518 trials

Success Rate

81.8%

-4.8% vs industry average

Late-Stage Pipeline

13%

68 trials in Phase 3/4

Results Transparency

41%

111 of 274 completed trials have results

Key Signals

73 recruiting111 with results42 terminated19 withdrawn

Enrollment Performance

Analytics

N/A
204(50.9%)
Phase 2
67(16.7%)
Phase 1
51(12.7%)
Phase 4
40(10.0%)
Phase 3
28(7.0%)
Early Phase 1
11(2.7%)
401Total
N/A(204)
Phase 2(67)
Phase 1(51)
Phase 4(40)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (518)

Showing 20 of 518 trials
NCT07599865Phase 2Recruiting

Periprosthetic Joint Infection Bubble Study

Role: lead

NCT07737925Phase 2Not Yet Recruiting

LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

Role: lead

NCT07737951Not ApplicableNot Yet Recruiting

Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

Role: lead

NCT07099638Phase 2Not Yet Recruiting

Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation

Role: collaborator

NCT05204030Not ApplicableCompleted

Hashtag HPV: HPV Vaccine Twitter Education Program

Role: collaborator

NCT06626516Phase 1Recruiting

Tebentafusp-tebn With LDT in Metastatic UM

Role: lead

NCT05055323Phase 1Active Not Recruiting

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

Role: lead

NCT04719273Phase 2Completed

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Role: lead

NCT07703462Phase 1Enrolling By Invitation

Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

Role: collaborator

NCT03911531Completed

Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops

Role: lead

NCT03682042Not ApplicableActive Not Recruiting

Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up

Role: collaborator

NCT07179458Not ApplicableEnrolling By Invitation

Criterion-learning Naming Treatment For Addressing Comprehension Deficits in Aphasia

Role: collaborator

NCT06240715Not ApplicableRecruiting

Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries- PreTerm

Role: collaborator

NCT07673198Not ApplicableNot Yet Recruiting

Effects of Semantic Context on Criterion-learning Naming Treatment in Aphasia

Role: collaborator

NCT06174727Recruiting

International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

Role: collaborator

NCT06747676Phase 1Suspended

GRAViceptive NEGlect Treatment in Acute Stroke Using Targeted Cranial ELECTrotherapy

Role: collaborator

NCT06483139Completed

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Role: collaborator

NCT06364709Not ApplicableCompleted

Criterion-learning Based Naming Treatment in Aphasia

Role: collaborator

NCT04868123Not ApplicableCompleted

Effects of TENS and Mindfulness Meditation in Persons With HIV-related Neuropathy

Role: collaborator

NCT01888198Active Not Recruiting

Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

Role: collaborator